Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Drug Discovery Today|October 11, 2005
BiTEs: bispecific antibody constructs with unique anti-tumor activityEvelyn Wolf, Robert Hofmeister, Peter Kufer, et al.
Molecular Immunology|December 20, 2005
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsSonja Offner, Robert Hofmeister, Andrea Romaniuk, et al.
Leukemia & Lymphoma|May 21, 2009
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomabDirk Nagorsen, Ralf Bargou, Dominik Ruttinger, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expressionKristan Meetze, Naveen K Mehta, Bochong Li, et al.
Immunotherapy|January 7, 2020
Implications of T cell receptor biology on the development of new T cell therapies for cancerIan R Hardy, Wolfgang W Schamel, Patrick A Baeuerle, et al.
International Journal of Oncology|November 8, 2006
Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approachFlavia Pernasetti, Jeffrey Nickel, Derek Clark, et al.
International Journal of Cancer|April 4, 2003
Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibodyPauline Wimberger, Wei Xiang, Doris Mayr, et al.
Frontiers in Oncology|September 10, 2024
Intratumoral injection and retention hold promise to improve cytokine therapies for cancerKarsten Sauer, Kavya Rakhra, Kaida Wu, et al.
Journal of Cancer Research and Clinical Oncology|June 24, 2003
Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cellsWei Xiang, Pauline Wimberger, Torsten Dreier, et al.
Mabs|November 26, 2010
Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110Silke Petsch, Olivier Gires, Dominik Rüttinger, et al.
Pageof 10